|
Variable
|
Standardized coefficients- Beta
|
T
|
P-value
|
|---|
|
Constant (SE)
|
0.417 (0.116)
|
3.580
|
0.002
|
|
Normalized Concentration of 6-TGNs
|
−0.489
|
−2.689
|
0.013*
|
|
Excluded variables
|
|
Age of onset, year
|
0.156
|
0.853
|
0.403
|
|
Disease duration, months
|
0.094
|
0.509
|
0.616
|
|
Treatment duration, months
|
−0.200
|
−1.106
|
0.281
|
|
Pre-therapy EDSS score
|
0.034
|
0.176
|
0.862
|
|
Post-therapy EDSS score
|
0.050
|
0.266
|
0.793
|
|
Mean CSF protein, mg/dl
|
−0.038
|
−0.198
|
0.845
|
|
Mean Concentration of CSF IgG, mg/ml
|
−0.158
|
−0.855
|
0.402
|
|
CSF IgG index (n%)
|
−0.287
|
−1.636
|
0.116
|
|
Normalized Concentration of MMPNs
|
−0.150
|
−0.751
|
0.461
|
-
NMOSD, AZA Azathioprine, BMI Body mass index, ARR Annual relapse rate, EDSS Expanded disability status scale, 6-TGN 6-thioguanine nucleotides, 6-MMPN 6-methylmercaptopurine nucleotides. All P-value <0.05 was considered statistically significant
